Immatics’ early data may add to growing optimism for cell therapies in solid tumors

Early Phase I data from Immatics’ autologous TCR cell therapies adds to growing optimism about the potential of cell therapies in solid tumors, where immunosuppressive microenvironments and a dearth of tumor-specific targets have been major barriers. 

The data, which mark the first clinical readout for  Immatics N.V. (NASDAQ:IMTX) since its July 2020 merger with a Perceptive Advisors-backed special purpose acquisition company (SPAC), pushed the company’s shares up $2.97 (26%) to $14.60 on Wednesday...